BRAF and plasma cell myeloma: The phase 2 CAPTUR study will treat a variety of tumor types, including multiple myeloma, according to targetable genetic abnormalities with BRAF V600-mutated disease receiving vemurafenib plus cobimetinib (NCT03297606).